Publications
Search our bibliography using the filters on the right-hand side.
Displaying 201 through 250 of 275 publications.
Skip to main content
Kiladjian JJ, Gisslinger H, Passamonti F, Neiderwieser D, Medelson E, Sirulnik LA, Copley-Merriman K, Zhou X. Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. Poster presented at the European School of Haematology (ESH) International Conference on Myeloproliferative Neoplasms; October 4, 2012. Previously presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Christiansen CF, Pedersen L, Sorensen HT, Rothman KJ. Methods to assess seasonal effects in epidemiological studies of infectious diseases-exemplified by application to the occurrence of meningococcal disease. Clin Microbiol Infect. 2012 Oct 1;18(10):963-9.
Nastaoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor M, Friedberg J, Link B, Cerhan J, Dawson K, Flowers C. Characteristics and effectiveness of rituximab (R) maintenance regimens among US patients diagnosed with follicular lymphoma (FL) 2004-2007. Poster presented at the 17th Congress of the European Hematology Association; June 14, 2012. Amsterdam, The Netherlands. [abstract] Haematologica. 2012 Jul 16; 97(s1):95-6. Previously presented at the 53rd Annual Meeting of the American Society of Hematology.
Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki RM, Taylor M, Friedberg J. Effectiveness of first-line chemoimmunotherapy regimens for patients diagnosed with follicular lymphoma in the United States: data from the national lymphocare study. Poster presented at the 17th Congress of the European Hematology Association; June 14, 2012.
Gnanasakthy A, Lewis SA, Clark MJ, Mordin MM, Evans E, DeMuro-Mercon CJ. The impact of primary endpoints on patient-reported outcome label claims. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 2012.
Lunt M, Glynn RJ, Rothman KJ, Avorn J, Sturmer T. Propensity score calibration in the absence of surrogacy. Am J Epidemiol. 2012 Jun 1;175(12):1294-302.
Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012 May 1;21(Suppl. 2):69-80.
Coon CD, Fehnel SE, Davis KH, Runken MC, Beach ME, Cady RK. The development of a survey to measure completeness of response to migraine therapy. Headache. 2012 Apr 1;52(4):550-72.
Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb;19(2):94-102.
Hareendran A, Gnanasakthy A, Winnette RM, Revicki D. Capturing patients' perspectives of treatment in clinical trials/drug development. Contemp Clin Trials. 2012 Jan;33(1):23-8.
Sherrill B, Sherif B, Amonkar MM, Maltzman J, O'Rourke L, Johnston S. Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib. Curr Med Res Opin. 2011 Dec 1;27(12):2245-52.
Bennett L, Zhao Z, Barber B, Zhou X, Peeters M, Zhang J, Xu F, Wiezorek J, Douillard JY. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Br J Cancer. 2011 Nov 1;105(10):1495-502.
Zhou X, Wang J, Zhang J, Zhu H. Comparison of mixed-effects model, pattern-mixture model, and selection model in estimating treatment effect using pro data in clinical trials. Poster presented at the JSM 2011; July 30, 2011. Miami Beach, FL.
Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sorensen HT. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. Br Med J. 2011 Jul 4;343:d3450. doi: 10.1136/bmj.d3450
Rahman MQ, Abeysinghe SS, Kelly S, Roskell NS, Shannon PR, Abdlseaed AA, Montgomery DMI. Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database. Br J Ophthalmol. 2011 Jul 1;95(7):966-70.
McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: uS FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011 Apr 1;11(2):163-9.
Odom D, Barber B, Bennett L, Peeters M, Zhao Z, Kaye J, Wolf M, Wiezorek J. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Colorectal Dis. 2011 Feb 1;26(2):173-81.
Chirila C, Earnshaw SR, Black L, McDade CL, Roskell NS, Shannon PR, Montorsi F, Andriole GL. Economic analysis: randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer. J Cancer Sci Ther. 2011;S3(004). doi: 10.4172/1948-5956.S3-004
Baldwin M, Spong A, Doward LC, Gnanasakthy A. Patient-reported outcomes, patient-reported information: from randomized controlled trials to the social web and beyond. Patient. 2011 Jan;4(1):11-7. doi: 10.2165
Chung RT, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Di Bisceglie AM. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Hepatology. 2010 Dec 1;52(6):1906-14. doi: 10.1002/hep.23947
Karve S, Misurski D, Miller JM, Davis KL. Long-term economic and clinical burden of complicated invasive meningococcal disease: evidence from a United States managed care population. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. [abstract] Value Health. 2010 Nov; 13(7):A432.
Amonkar MM, Sherrill B, Zhou X. A review of the impact of lapatinib on health-related quality of life of patients with newly diagnosed and refractory metastatic breast cancer. Poster presented at the 2010 Breast Cancer Symposium; October 4, 2010. National Harbor, MD.
Pockros PJ, Hamzeh FM, Martin P, Lentz E, Zhou X, Govindarajan S, Lok AS. Histologic outcomes in hepatitis C–infected patients with varying degrees of virologic response to interferon-based treatments. Hepatology. 2010 Oct 1;52(4):1193-200.
Chung RT, Bisceglie A, Poordad FF, Hassanein T, Zhou X, Lentz E, Prabhakar A, Hamzeh FM. Association of host pharmacodynamic effects and virologic response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis c. Poster presented at the 2010 Digestive Disease Week; May 1, 2010. New Orleans, LA. [abstract] Gastroenterology. 2010 May; 138(5_suppl_1):S-841.
Ervin CM, Fehnel S, Carson R, Kurtz C, Shiff S, Johnston J. Selecting chronic constipation (CC) clinical trial endpoints: incorporating the patient's voice. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 28, 2010. [abstract] Value Health. 2010 May; 13(3):A74.
Johannes C, Odom D, Bennett L, Foley D. The impact of menopause status on formal vs. informal care-seeking behavior in women with decreased sexual desire with associated distress. J Sex Med. 2010 May 1;7(Suppl. 3):123.
Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010 Mar 15;25(4):474-80.
Johannes CB, Clayton AH, Odom DM, Rosen RC, Russo PA, Shifren JL, Monz BU. Distressing sexual problems in United States women revisited: prevalence after accounting for depression. J Clin Psychiatry. 2009 Dec 1;70(12):1698-706.
Sherrill B, Sherif BN, Amonkar M, Wu Y, Maltzman J, O'Rourke L, Johnston S. Quality of life and quality-adjusted survival (Q-TWIST) in patients receiving lapatinib plus letrozole as first-line therapy in hormone receptor positive, her2+ metastatic breast cancer. Poster presented at the Cancer Symposium of the American Society of Clinical Oncology; October 10, 2009.
Rosen R, Shifren J, Monz B, Odom D, Russo P, Johannes C. The predictors of sexual distress in women with low sexual desire. Presented at the Annual Meeting of the International Society for the Study of Women's Sexual Health; September 1, 2009.
Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med. 2009 Jun 1;6(6):1549-60.
Lee LJ, Nelson LM, McLeod LD, Hill CD, Sweeney CT. Effects of insulin therapy on the Diabetes Symptom Checklist-Revised (DSC-R): data from a large insulin clinical trial. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 21, 2009. [abstract] Value Health. 12(3):A105.
Arbuckle R, Atkinson M, Clark MJ, Abetz-Webb L, Lohs J, Kuhagen I, Harness J, Draelos Z, Thiboutot D, Blume-Paytavi U, Copley-Merriman K. Patient experiences with oily skin: the qualitative development of content for two new patient reported outcome questionnaires. Poster presented at the American Academy of Dermatology Meeting; March 1, 2009.
Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A, Soper JT, Havrilesky L. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol. 2009 Jan 1;112(1):150-4.
Mladsi DM, Irish WD, Copley-Merriman K, Bhandary D. Statistical measures of treatment effects in oncology: what are we missing? Presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece.
Odom D, Devercelli G, Bennett L, Peeters M, Wolf M, Amado R. Health-related quality of life (HRQOL) and colorectal cancer (CRC) symptoms in metastatic CRC: panitumumab plus best supportive care (BSC) versus bsc alone by kras tumor status. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 12, 2008. [abstract] Value Health. 2008 Nov; 11(6):487.
Turk DC, Dworkin RH, McDermott MP, Bellamy N, Burke LB, Chandler JM, Cleeland CS, Cowan P, Dimitrova R, Farrar JT, Hertz S, Heyse JF, Iyengar S, Jadad AR, Jay GW, Jermano JA, Katz NP, Manning DC, Martin SA, Max MB, McGrath P, McQuay HJ, Quessy S, Rappaport BA, Revicki DA, Rothman M, Stauffer JW, Svensson O, White RE, Witter J. Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials. Pain. 2008 Oct;139(3):485-93. doi: 10.1016/j.pain.2008.06.025.
Odom DM, Wang J, Irish W. Meta-regression of placebo response. Poster presented at the Proceedings of the American Statistical Association, Biopharmaceutical Section; September 2008. Washington, DC.
Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008 Mar;35(3):502-14.
Schneeweiss S, Patrick AR, Sturmer T, Brookhart MA, Avorn J, Maclure M, Rothman KJ, Glynn RJ. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007 Oct 1;45(10 - Suppl 2):S131-42.
Dickinson KL, Pattanayak SK, Yang J, Patil SR, Praharaj P, Mallick RK, Blitstein JL, Poulos C. Nature's call: can social mobilization promote toilet use and reduce child diarrhea? Results from a community randomized trial in Orissa, India. Presented at the Infectious Diseases Conference at Cornell University; September 2007.
Zhou X, Sherrill BH, Wang J. Assessing baseline and post-baseline effects in repeated measures data analysis: an example using smoking cessation data. Presented at the ASA JSM 2007; August 1, 2007. Salt Lake City, UT.
Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol. 2007 May 1;5(5):534-40.
Dickinson KL, Pattanayak SK, Yang J, Patil SR, Praharaj P, Mallick RK, Blitstein JL, Poulos C. Nature's call: can a social mobilization campaign lead households to use toilets and reduce diarrhea? Results from a randomized trial in Orissa. Poster presented at the 4th Minnesota International Economic Development Conference at the University of Minnesota; May 2007.
Gilsenan AW, Wang J, Midkiff KD, Andrews EB. Assessing the impact of potential selection bias on prevalence estimates of lower urinary tract symptoms in a primary care setting. Poster presented at the 23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 2007.
Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, Berchuck A, Barrett JC, Rodriguez GC. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006 Nov 1;103(2):535-40.
Gilsenan A, Zhou X, Coste F, Allshouse AA. Comparison of data from a US national survey (NHANES) with data from a cohort recruited from the internet. Poster presented at the 22nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2006. Lisbon, Portugal.
Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006 May 1;59(5):437-47.
Havrilesky LJ, Cragun JM, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol. 2005 Dec 1;99(3):689-95.
Gregson N, Sparrowhawk K, Mladsi DM. Global pricing and reimbursement strategy: an integrated analytical framework. Presented at the 2005 ISPOR 8th Annual European Congress; November 8, 2005. Florence, Italy.